Corvus Pharmaceuticals (CRVS) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Corvus Pharmaceuticals (CRVS) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, gaining 12.8% versus a loss of 50.0%. Over five years, CRVS leads with a +183.6% price change compared with -47.1% for SNDX. Corvus Pharmaceuticals is the larger company by market cap ($815.7 million vs $785.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVS | SNDX |
|---|---|---|
| Share price | $9.67 | $8.72 |
| Market cap | $815.69M | $785.05M |
| 1-day change | -3.40% | -4.49% |
| YTD return | +25.58% | -58.50% |
| 1-year return | +12.84% | -50.00% |
| 5-year return | +183.58% | -47.09% |
| EPS (TTM) | $-0.72 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $172.35M |
| Revenue growth (YoY) | — | +627.84% |
| Net income (latest FY) | $-15.28M | $-285.42M |
| Operating margin | — | -158.45% |
| Net margin | — | -165.60% |
| 52-week high | $26.95 | $25.59 |
| 52-week low | $6.39 | $8.41 |
| Distance from 52-week high | -64.12% | -65.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +225.75% | +306.54% |
| Average volume | 1.05M | 2.63M |
| Shares outstanding | 84.35M | 90.03M |
| Employees | 37 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRVS has outperformed SNDX by 62.8 percentage points over the past year.
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
CRVS vs SNDX FAQ
Which is bigger, Corvus Pharmaceuticals or Syndax Pharmaceuticals?
Corvus Pharmaceuticals (CRVS) is larger, with a market capitalization of $815.69M compared with $785.05M for Syndax Pharmaceuticals (SNDX).
Which stock has performed better over the past year, CRVS or SNDX?
CRVS returned +12.84% over the past 12 months, compared with -50.00% for SNDX (price return, excluding dividends). Past performance does not predict future results.
Are Corvus Pharmaceuticals and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.